MedCity News May 10, 2021
Incubated by Flagship Pioneering, biotech firm Laronde is developing endless RNA, or eRNA, a new class of medicines that goes beyond messenger RNA-based therapies. Flagship is backing the startup $50 million in Series A financing.
Messenger RNA vaccines for Covid-19 showed how this technology could turn the body’s cells into factories that churn out useful proteins, at least temporarily. Biotech startup Laronde is developing a way to make this protein production endless, potentially leading to new medicines that are more stable and longer lasting.
On Monday, Cambridge, Massachusetts-based Laronde unveiled its technology along with $50 million in Series A financing. The cash comes from Flagship Pioneering, the venture capital firm that formed mRNA biotech Moderna and has been incubating Laronde...
Today's Sponsors
Today's Sponsor